secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viatris Inc (VTRS)
CIK:        0001792044
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001792044-25-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viatris reports FY2024 revenue $14.7B, GAAP net loss $634M, adj EPS $2.65; guides 2025 share buybacks $500-650M
--------------------------------------------------------------------------------

- FY2024 total revenues $14.7B; GAAP net loss $634M ($0.53 diluted loss); adjusted EPS $2.65.
- Free cash flow $2.0B (incl. ~$650M transaction costs) exceeded guidance; repaid $3.7B debt; leverage 2.9x.
- New product revenues $582M; 2025 expects six Phase 3 readouts for selatogrel, cenerimod, sotagliflozin.
- 2025 guidance includes Indore facility warning letter/import alert impact; enterprise cost review initiated.
- Plans $500M-$650M share repurchases in 2025; returned $825M to shareholders in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1792044/000179204425000004/0001792044-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1792044/000179204425000004/vtrs-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001792044-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer